Page 4 of 8: studies 61 to 80 of 156, newest first. Back to the addiction overview
Expert Review of Clinical Pharmacology July 29, 2025
1. Substance Use Disorder (SUD) continues to have a growing global impact, affecting an estimated 64 million individuals worldwide [1]. While pharmacotherapies are available for opioid, tobacco, an...
Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted psychotherapy for patients with comorbid...
International Journal of Community Medicine and Public Health July 17, 2025 Alanoud K. Albanna, Zayed M. Alnefaie, Atheer M. Saleh et al.
Ketamine’s rapid action and diverse physiological effects have made it an important drug in both anesthesia and mental health treatment. Clinically, it offers unique dissociative anesthetic properties, preserving stable vital signs during sedation and analgesia. Beyond its numbing effect, studies explore its influence on N-methyl-D-aspartate (NMDA) receptors and wider neurochemical systems...
bioRxiv Preprint Server July 16, 2025 Borjan Milinkovic, Anil K. Seth, Lionel Barnett et al. 2 citations preprint
Conscious experience depends on the coordinated activity of neural processes that span multiple scales—from synapses to whole-brain dynamics. A recently introduced measure, dynamical independence, identifies, characterises and quantifies these multi-scale relationships using an information-theoretic dimensionality-reduction approach. Here, we use DI to examine changes in emergent dynamical...
Current microbiology July 15, 2025 Gokul Sudhakaran, Shreya Chakraborty, Ashok Kumar et al. 2 citations
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jurisdictions. This review aims to...
Current Topics in Behavioral Neurosciences July 12, 2025 Wolfgang H. Sommer, Rainer Spanagel
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, marked by both persistent challenges and emerging opportunities. We reflect on the translational gap that has stalled the development of new treatments for alcohol use disorder (AUD), despite decades of promising preclinical findings. Particular...
Journal of Molecular Neuroscience July 12, 2025 Weihao Fan, Yi Ye, Hongkun Yang et al. 1 citation
Ketamine is a synthesized anesthetic drug that was used extensively as a surgical anesthetic in the 1960s. Currently, ketamine is being investigated extensively for its potential as a treatment for depression. However, the addictive nature of ketamine has become an issue that cannot be ignored at this stage. As of now, there is no clear understanding of the changes in striatal metabolites and...
Journal of Psychopharmacology July 11, 2025 Diana Glenn, Seung Hee Choi, Rick S. Zimmerman 1 citation
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction. Methods: A systematic...
CNS Drugs July 10, 2025 Eric A. Miller, Christy Capone, Erica Eaton et al. 4 citations
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lysergic acid diethylamide (LSD), and several contemporary trials of psilocybin and ayahuasca for this indication. Herein, we characterize foundational studies from the 1950s to the present, with emphasis on key design factors that varied considerably...
Psychiatry Research July 5, 2025 Maria Helha Fernandes-Nascimento, Priscila Weber, André Brooking Negrão 4 citations
LSD (lysergic Acid Diethylamide), a psychedelic compound, has been investigated in recent studies for the treatment of mental disorders. We analyzed the efficacy and safety of LSD in the treatment of mental disorders and substance use disorders in adult patients. We searched Embase, PubMed, Scopus, PsycINFO, the Cochrane Library, CENTRAL, BVS, EBSCO, Epistemonikos, and the grey literature for...
Psychiatry Research July 1, 2025 Mazyar Fathi, Mohammad Navid Ebrahimi, Mohammad Banazadeh et al. 6 citations
Neurofeedback (NF), a form of biofeedback, is used to enhance the self-regulation of brain functions by assessing brain activity and delivering feedback signals to ameliorate emotional attributes, cognitive functions, and behaviors. Despite the potential role of NF in substance use disorder (SUD) treatment, a number of gaps such as variations in NF methods persist. This study aims to address...
Drug and Alcohol Dependence July 1, 2025 Dilara Bahceci, Krista J. Siefried, Maureen Steele et al.
Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the...
Molecules June 30, 2025 Ewa Gibuła-Tarłowska, Anna Wiszniewska, Magdalena Turyk et al. 10 citations
Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to its use in anesthesia, ketamine exerts potent analgesic effects via N-methyl-D-aspartate (NMDA) receptor antagonism, modulating pain perception and reducing central sensitization, particularly in chronic and neuropathic pain conditions. Emerging...
Social Theory & Health June 27, 2025 Johan Söderberg, Jakob Lundgren 2 citations
Abstract The controlled substance “ibogaine” is reported to have unique addiction-interrupting properties. Due to its illegal status, the drug's application for treating substance dependency has been explored by a network of addicts and harm reduction activists in underground and off-shore clinics. The article investigates the strategies that practitioners have adopted to mitigate harm from...
bioRxiv Preprint Server June 24, 2025 Marco German Ghilotti, Ricardo Petrilli Fortuna, Kofi Osei-Abrefa Ayensu et al. preprint
Background The use of methamphetamine has continued to rise in the US. In addition to facilitating dopamine neurotransmission, methamphetamine indirectly increases glutamate release which activates N-methyl-D-aspartate receptors (NMDARs). Ketamine is a noncompetitive NMDAR antagonist. Ketamine also has actions on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and...
Beni-Suef University Journal of Basic and Applied Sciences June 20, 2025 Danladi Chiroma Husaini, Joel H. Chiroma, Innocent Ejiofor Nwachukwu et al.
Abstract Background Latin America and the Caribbean region are currently faced with the challenges of drug and substance use leading to violence and crime, especially among the younger populations. The complex nature of substance use disorder (SUD), the cost and adverse effects of conventional therapies, the deeply rooted cultural practices of medicinal plants usage, and the abundance of...
Preprints.org June 19, 2025 Danial Daroui, Andrea Mastrostefano, Flavio Davini et al. 1 citation preprint
Background: Alcohol Use Disorder (AUD) is a chronic pathological condition with significant burdens throughout the world. Despite the effectiveness of the current pharmacological treatments, the ongoing issues with AUD and the high relapse rates necessitate the exploration of innovative therapies, including the use of psychedelic drugs, which have shown promising initial results. The purpose of...
June 16, 2025 Bruno Ramos Gomes, Bruno Rasmussen Chaves
Ibogaine, derived from the Iboga (Tabernanthe iboga), a shrub of central Africa, has a history of medical and entheogenic ritual use. Its modern use followed the serendipitous discovery, among heroin users in 1962, that it interrupted heroin addiction. Efforts to engage the scientific community in the clinical science of ibogaine had limited success but led to an underground treatment movement...
June 10, 2025 Gabrielle Agin-Liebes, Petros Petridis, Richard J. Zeifman et al. 1 citation preprint
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking...
Psychedelics June 10, 2025 Stephen Ross
Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York University (NYU) Grossman School of Medicine who has transformed the landscape of psychedelic research since 2006. In this Genomic Press Interview, Dr. Ross reveals how as co-director of the NYU Langone Center for Psychedelic Medicine and director of its...